Sector: Health Technology
Industry: Pharmaceuticals: Major
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
NRx Pharmaceuticals (NRXP) said Tuesday it has submitted a revised investigational new drug module with the US Food and Drug Administration confirming that Nephron Pharmaceuticals is ready to supply its COVID-19 drug candidate Zyesami on a commercial scale.
The FDA will include the module in its rolling review of the new drug application for Zyesami, the company said.
NRx also recently received notification that inspection at a separate manufacturing facility for Zyesami in Europe has been completed. It is now awaiting QP Declaration, which is required by the EU regulatory authorities for the release of the drug.
Shares in the drugmaker rose 3.1% in Tuesday premarket trading.
New Target : USD 64
Resistance 3 : USD 49.20
Resistance 2 : USD 26.27
Resistance 1 : USD 11.06
Support Level : USD 6.17
**Disclaimer - This is not a financial advice, please trade with caution and on your own risk. This prediction Based on My Dreams.
Do not view this idea as a recommendation for trading or investing. Risk Only What You Can Afford. Always Use a Stop Loss. Past performance is not necessarily a guide to future performance.
I would appreciate your feedback on my analysis.
Industry: Pharmaceuticals: Major
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
NRx Pharmaceuticals (NRXP) said Tuesday it has submitted a revised investigational new drug module with the US Food and Drug Administration confirming that Nephron Pharmaceuticals is ready to supply its COVID-19 drug candidate Zyesami on a commercial scale.
The FDA will include the module in its rolling review of the new drug application for Zyesami, the company said.
NRx also recently received notification that inspection at a separate manufacturing facility for Zyesami in Europe has been completed. It is now awaiting QP Declaration, which is required by the EU regulatory authorities for the release of the drug.
Shares in the drugmaker rose 3.1% in Tuesday premarket trading.
New Target : USD 64
Resistance 3 : USD 49.20
Resistance 2 : USD 26.27
Resistance 1 : USD 11.06
Support Level : USD 6.17
**Disclaimer - This is not a financial advice, please trade with caution and on your own risk. This prediction Based on My Dreams.
Do not view this idea as a recommendation for trading or investing. Risk Only What You Can Afford. Always Use a Stop Loss. Past performance is not necessarily a guide to future performance.
I would appreciate your feedback on my analysis.
Trade active:
NRx Pharmaceuticals (NRXP) said Tuesday it has submitted a revised investigational new drug module with the US Food and Drug Administration confirming that Nephron Pharmaceuticals is ready to supply its COVID-19 drug candidate Zyesami on a commercial scale.
The FDA will include the module in its rolling review of the new drug application for Zyesami, the company said.
NRx also recently received notification that inspection at a separate manufacturing facility for Zyesami in Europe has been completed. It is now awaiting QP Declaration, which is required by the EU regulatory authorities for the release of the drug.
Shares in the drugmaker jumped 30% during Tuesda
The FDA will include the module in its rolling review of the new drug application for Zyesami, the company said.
NRx also recently received notification that inspection at a separate manufacturing facility for Zyesami in Europe has been completed. It is now awaiting QP Declaration, which is required by the EU regulatory authorities for the release of the drug.
Shares in the drugmaker jumped 30% during Tuesda
This is a Good Sign. Early Tomorrow we can see many Buyers Coming in.
Cheers ...